Suggestions
Idioma
Guide for authors
Searcher
Journal Information
Vol. 22. Issue 8.
(October 2026)
Cite
Cite
Share
Download PDF
More article options
Visits
594
Vol. 22. Issue 8.
(October 2026)
Original

Tendencias y variabilidad en el uso de glucocorticoides en los pacientes con lupus eritematoso sistémico incluidos en el registro RELESSER-PROS

Trends and variability in the use of glucocorticoids in patients with systemic lupus erythematosus included in the RELESSER-PROS registry
Visits
594
Inigo Rua-Figueroaa,
Corresponding author
iruafer@gobiernodecanarias.org

Autor para correspondencia.
, David Fernández-Fernándezb, Zulema Plazac, Karen Robertsd, Belén Serrano-Benaventee, María Galindo-Izquierdof, Jaime Calvo Aleng, Raúl Menorh, Natalia Mena-Vázquezi, Esther Uriartej, Eva Tomerok, Mercedes Freirel, Clara Sanguesam, Silvia Gómez-Sabatern, Loreto Horcadao, Nuria Lozano-Rivasp, María Jesús García-Villanuevaq, Adrián Quevedo-Rodríguezr, Elvira Díez-Álvarezs, Javier Narváezt..., Carlota Iñiguezu, Javier Loricerav, Javier Novoaw, Esther Ruiz-Luceax, José Rosasy, Lorena Expósitoz, Irene Carrión-Barberaaa, Eva Salgadoab, José Luis Andreuac, Elena Aurrecoecheaad, Carlos Montillaae, Jose Andrés Román Ivorraaf, Gema Bonillaag, Tatiana Cobo-Ibañezah, Alejandro Muñoz-Jiménezai, Vicente Torrente-Segarraaj, Marta Arévalo-Salaetak, Angela Pecondón-Españolal, Ana Pérez-Gómezam, Eduardo Floresan, Jose M. Pego-ReigosaaoVer más
a Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, España
b Meixoeiro Hospital, Vigo, España
c Research Unit of Spanish Society of Rheumatology, Madrid, España
d Research Unit of Argentine Society of Rheumatology, Buenos Aires, Argentina
e Hospital Gregorio Marañon, Madrid, España
f Hospital 12 de Octubre, Madrid, España
g Rheumatology, Hospital Universitario Araba, Vitoria-Gasteiz, España
h Rheumatology, Jerez de la Frontera General Hospital, Jerez de La Frontera, España
i Málaga University Hospital, España
j Donostia University Hospital San Sebastian, España
k Hospital Universitario de la Princesa, Madrid, España
l Rheumatology, A Coruna University Hospital, A Coruna, España
m University Hospital Germans Trias i Pujol, Badalona, España
n University Hospital of Alicante, España
o Navarra Hospital Complex, Pamplona, España
p Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, España
q Ramón y Cajal Hospital, Madrid, España
r Hospital Universitario de Gran Canaria Dr Negrín , Las Palmas de Gran Canaria, España
s University Hospital of León, España
t Rheumatology, IDIBELL -Hospital Universitario de Bellvitge, Barcelona, España
u University Hospital Lucus Augusti, Lugo, España
v Marqués de Valdecilla U. Hospital, Santander, España
w Gran Canaria Insular Hospital, Las Palmas, España
x Basurto U. Hospital, Bilbao, España
y Hospital Marina Baixa, Villajoyosa, España
z University Hospital of Canarias, Tenerife, España
aa Del Mar Hospital, Barcelona, España
ab Rheumatology, Hospital Clínico Santiago de Compostela, España
ac Puerta de Hierro Majadahonda U. Hospital, Madrid, España
ad Hospital Sierrallana, Torrelavega, España
ae Salamanca U. Hospital, España
af La Fe University and Polytechnic Hospital, Valencia, España
ag La Paz U. Hospital, Madrid, España
ah Infanta Sofia Hospital San Sebastián de los Reyes, España
ai Virgen del Rocío U Hospital, Sevilla, España
aj Hospital de Sant Joan Despí Moisès Broggi, Barcelona, España
ak Consorci Corporació Sanitària Parc Taulí, Barcelona, España
al Hospital Universitario Miguel Servet, Zaragoza, España
am Hospital Universitario Príncipe de Asturias, Madrid, España
an Hospital Universitario Dr. Peset, Valencia, España
ao Rheumatology Galicia Sur Health Research Institute (IISGS), IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Vigo, España
Ver más
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Resumen
Contexto

Las recomendaciones de manejo del lupus eritematoso sistémico (LES) de las principales sociedades científicas preconizan un uso cada vez más restrictivo de glucocorticoides (GC). Sin embargo, no hay datos a gran escala de su uso en España en la práctica clínica reumatológica, ni de la adecuación a las recomendaciones vigentes. El objetivo del estudio fue analizar este aspecto del tratamiento del LES por Comunidades Autónomas (CCAA).

Métodos

Estudio observacional descriptivo, longitudinal prospectivo, de pacientes con LES incluidos en la cohorte RELESSER-PROS acerca de los patrones de uso de GC incluyendo rangos de dosificación y tendencias en el tiempo.

Resultados

Se incluyeron un total de 1.432 pacientes, 89,8% mujeres, edad media de 56 años (± 13,6), con una mediana de seguimiento de 3,80 (2,06, 4,18) años, entre los años 2015 y 2021. Mediana de S-SLEDAI (cinco visitas): 2,00 (Q-Q3) (0-4,00), PGA: 0,3 (0, 0,9). Mediana de SLICC/ARC DI (SDI) basal: 0 (0-1,00), media: 0,83 (± 1,20). Entre 30% y el 61% de los pacientes recibían GC en visita basal y entre el 17% y el 50% en la final (V5). Se observó descenso progresivo del porcentaje de pacientes recibiendo GC en la mayoría de las CCAA, alcanzando el mínimo en V5. En cuanto a las dosificaciones de GC entre el 71,45% y el 89,47% de los pacientes, por CCAA, satisfacían el criterio de≤5mg de prednisona en V5, con un delta entre la CCAA con mayor porcentaje y la de menor de 18 puntos porcentuales. Este porcentaje se incrementó entre la visita 1 y la visita 5 en todos los casos.

Conclusiones

El uso de GC a dosis bajas es frecuente en los pacientes lúpicos españoles, si bien se observa una clara tendencia al descenso en su utilización. La mayoría de los pacientes satisfacen el objetivo de dosificación recomendado. Existen diferencias entre las distintas CCAA en el empleo de GC y en su dosificación.

Palabras clave:
Lupus eritematoso sistémico
Glucocorticoides
Patrones
Abreviaturas:
LES
GC
HCQ
SDI
SELENA-SLEDAI
PGA
SFI
CCAA
ACR
EULAR
Abstract
Context

Recommendations for the management of systemic lupus erythematosus (SLE) advocate increasingly restrictive use of glucocorticoids (GC). However, there are no wide-scale data on their use in clinical practice from Spain, nor on compliance with current recommendations. The objective was to analyze this aspect of SLE treatment by autonomous communities (CCAA).

Methods

Observational, descriptive, longitudinal, and prospective study of patients with SLE included in RELESSER-PROS regarding patterns of GC use.

Results

1,432 patients were included, 89.8% women, mean age 56 years (±13.6), median follow-up 3.80 [2.06, 4.18] years, from 2015 to 2021. Median S-SLEDAI (5 visits): 2.00 [Q-Q3] [0-4.00], PGA: 0.3 [0,0.9]. Median SLICC/ARC DI: 0 [0-1.00], mean: 0.83 (±1.20). Between 30% and 61% of patients received GC at baseline and between 17% and 50% at the end (V5). A progressive decrease in the percentage of patients receiving GC was observed in most CCAs, reaching the minimum at V5. Between 71.45% and 89.47% of patients, by autonomous community, met the criterion of ≤5mg of prednisone at V5, with a delta between the autonomous community with the highest percentage and the lowest of 18 points. This percentage increased between visit 1 and visit 5 in all cases.

Conclusions

The use of low-dose GCs is common in Spanish lupus patients, although there is a clear downward trend in their use. Most patients typically reach the recommended dose. There are differences between the different autonomous communities in the use of GCs and their dosage.

Keywords:
Systemic lupus erythematosus
Glucocorticoids
Patterns

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to
Reumatología Clínica (English Edition)
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Bibliografía
[1]
E. Enríquez-Merayo, M.J. Cuadrado.
Steroids in Lupus: Enemies or Allies.
J Clin Med., 12 (2023), pp. 3639
[2]
I. Altabás-González, I. Rua-Figueroa, C. Mouriño, et al.
Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis.
Lupus Sci Med., 11 (2024), pp. e001064
[3]
A. Zonana-Nacach, S.G. Barr, L.S. Magder, M. Petri.
Damage in SLE and its association with corticosteroids.
[4]
Í. Rúa-Figueroa, J. López-Longo, M. Galindo-Izquierdo, et al.
Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus.
Semin Arthritis Rheum., 47 (2017), pp. 38-45
[5]
M.G. Tektonidou, A. Dasgupta, M.M. Ward.
Risk of serious infections in patients with SLE receiving immunosuppressive agents: Meta-analysis.
Arthritis Care Res., 68 (2016), pp. 311-318
[6]
S. Sciascia, S.G. Foddai, M. Arbrile, et al.
Assessing the steroid-sparing effect of biological agents in randomized controlled trials for lupus: a scoping review.
Immunol Res., 72 (2024), pp. 538-553
[7]
A. Fanouriakis, M. Kostopoulou, A. Alunno, et al.
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Ann Rheum Dis., 78 (2019), pp. 736-745
[8]
A. Fanouriakis, M. Kostopoulou, A. Alunno, et al.
2023 Update of the EULAR recommendations for the management of systemic lupus erythematosus.
Ann Rheum Dis., 82 (2023), pp. 15-27
[9]
L.R. Sammaritano, A. Askanase, B.L. Bermas, et al.
2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus.
Arthritis Rheumatol., (2025),
[10]
I. Rua-Figueroa, R. Cervera, M. Freire-González, et al.
Spanish SLE Prospective Observational Cohort Study (SPOCS). Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data.
Lupus Sci Med., 12 (2025), pp. e001597
[11]
M.B. Urowitz, D.D. Gladman, B.D. Tom, et al.
Glucocorticoid use in SLE: Patterns and outcomes in the SLICC cohort.
Arthritis Care Res (Hoboken)., 72 (2020), pp. 263-270
[12]
P. Katz, S. Pedro, J. Park, J. Choi, K. Michaud.
The Burden of Glucocorticoids: Patterns of Use, Adverse Health Conditions, and Health Care Use in Two Cohorts With Systemic Lupus Erythematosus.
ACR Open Rheumatol., 6 (2024), pp. 918-926
[13]
M. Walsh, D. Jayne, L. Moist, M. Tonelli, N. Pannu, B. Manns.
Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis.
Lupus., 19 (2010), pp. 628-633
[14]
P. Ngamjanyaporn, E.M. McCarthy, J.C. Sergeant, et al.
Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey.
Lupus Sci Med., 4 (2017), pp. e000173
[15]
I. Rúa-Figueroa Fernández de Larrinoa, J.M. Pego-Reigosa.
Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain.
Reumatol Clin (Engl Ed)., 17 (2021), pp. 245-249
[16]
I. Rúa-Figueroa, F.J. López-Longo, J. Calvo-Alén, et al.
National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: objectives and methodology.
Reumatol Clin., 10 (2014), pp. 17-24
[17]
R. van Vollenhoven, A. Voskuyl, G. Bertsias, et al.
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).
Ann Rheum Dis., 76 (2017), pp. 554-561
[18]
Z. Touma, S. Kayaniyil, A. Parackal, et al.
Unfavorable Outcomes Associated With Glucocorticoid Use in Current Standard-of-Care Management of Systemic Lupus Erythematosus in Canada.
ACR Open Rheumatol., 6 (2024), pp. 531-539
[19]
Y. Katsumata, E. Inoue, M. Harigai, Asia-Pacific Lupus Collaboration, et al.
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study.
Ann Rheum Dis., 83 (2024), pp. 998-1005
[20]
M. Aringer, L. Arnaud, R.A. Furie, et al.
Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS).
Lupus Sci Med., 12 (2025), pp. e001336
[21]
G. Ruiz-Irastorza, D. Paredes-Ruiz, L. Dueña-Bartolome, et al.
No Effect of Low-Dose Glucocorticoid Maintenance Therapy on Damage in SLE Patients in Prolonged Remission: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort.
J Clin Med., 13 (2024), pp. 6049
[22]
L. Ji, W. Xie, Z. Zhang.
Low-dose glucocorticoids should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual.
Rheumatology (Oxford)., 60 (2021), pp. 5517-5526
[23]
I. Rúa-Figueroa, D. Fernández-Fernández, Z. Plaza, et al.
P114. Just a little or not at all?. differences in organ damage progression according to glucocorticoids dosages in the treatment of systemic lupus erythematosus patients data from RELESSER-PROS Spanish multicenter prospective cohort.
Reumatol Clin., 21 (2025), pp. 250
[24]
J. Little, B. Parker, M. Lunt, et al.
Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.
Rheumatology (Oxford)., 57 (2018), pp. 677-687
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools